Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lux Biosciences sees early promise in dry eye drug

This article was originally published in Scrip

Executive Summary

Lux Biosciences' topical formulation of voclosporin, LX214, for the treatment of chronic inflammatory eye diseases, looks promising after it gave a significantly higher concentration in the eye than twice daily ciclosporin A (Allergan's Restasis) in animal models. In preclinical studies, concentrations of LX214 reached therapeutic levels in tear fluid and most ocular tissues, including conjunctiva, cornea, eyelids, sclera and lacrimal glands after single or multiple topical applications. Blood levels remained at or near baseline and there was minimal overflow of the candidate to the opposite, non-treated eye. There was no evidence of eye irritation and LX214 did not bind to melanin. LX214, a calcineurin inhibitor, is a clear, aqueous formulation, which the company says is unlike other topical dry eye products. Lux licensed it from Isotechnika and is investigating it as a potential treatment for conditions such as dry eye syndrome, blepharitis and atopic keratoconjunctivitis. It will initially be developed for dry eye syndrome, and an IND submission and first human studies are anticipated for the second half.

Advertisement
Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC000013

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel